Background and Objective: Hedgehog inhibitors such as vismodegib are targeted drugs widely used for the treatment of basal cell carcinomas; however, their use is significantly limited by frequent systemic side effects due to oral administration route. We aim to use ablative fractional laser (AFL) to enable the topical delivery of vismodegib to relevant dermal depths. Materials and Methods: Pig skin was treated in vitro with a fractional 10,600 nm CO 2 laser at 0 or 80 mJ/ microbeam and exposed to vismodegib (6.4 mmol/L) in Franz-diffusion cells for 0.5, 4, and 24 hours (n ¼ 54 samples), either formulated in a micro-emulsion composed of soybean oil and Tween 80 or dissolved in ethanol as vehicle control. Vismodegib biodistribution was studied at specific skin depths from 0 to 1,800 mm (incremental steps of 300 mm) by mass spectrometry. Results: Combination of AFL and vismodegib emulsion substantially enhanced the delivery of drug into the skin. Emulsion formulation alone yielded higher vismodegib skin concentrations compared to vehicle control in superficial and mid-dermis (0-900 mm, P ¼ 0.002-0.015). The over-all highest concentration found (554.5 mmol/L) was reached at 24 hours in superficial (0-300 mm) AFL exposed skin, 7.6-fold higher than vehicle control (P ¼ 0.002) and 9.7-101.6 fold higher than previously reported steady-state plasma concentrations in patients treated with oral vismodegib (5.5-56.9 mmol/L). Compared to intact skin, AFL exposure significantly increased skin concentrations of vismodegib even in deep skin layers (24 h, 900-1,800 mm, emulsion: 8.7-74.3 mmol/L vs. 0.0-0.0 mmol/L, P ¼ 0.004-0.048; vehicle control: 23.7-50.6 mmol/L vs. 0.0-1.6 mmol/L, P ¼ 0.002). The total delivery of vismodegib-emulsion into mid-deep dermal skin layers from 600 to 1,800 mm was for AFL exposed skin 8.2 fold higher than intact skin. Also, delivery of emulsion vismodegib by AFL was timedependent as seen by the continuous increase in concentrations found over time, with highest uptake detected after 24 hours (4-24 hours, 0-900 mm, P ¼ 0.002-0.004). Conclusion: AFL enhances topical delivery of microemulsion formulated vismodegib, reaching concentrations similar to or above plasma concentrations previously reported in patients receiving oral vismodegib. Lasers Surg. Med. 51:79-87, 2019.
INTRODUCTION
Targeted topical drug delivery shows potential over systemic delivery in the treatment of dermatological disorders, such as non-melanoma skin cancer, due to the reduced risk of systemic adverse reactions and the potential of achieving greater local drug concentrations. However, the stratum corneum forms an efficient diffusion barrier and successful topical delivery requires distinct compound characteristics regarding molecular size and chemical properties [1] . Numerous preclinical studies and clinical trials on various drugs support the use of ablative fractional laser (AFL) to increase skin concentrations of topically applied drugs [2] and the clinical potential has in particular been demonstrated in treatment of actinic keratoses with photodynamic therapy [3, 4] . AFL penetrates stratum corneum and skin layers below in a grid of discrete microscopic ablated zones, disrupting the skin barrier [5] , and facilitating increased uptake from a diverse range of topically applied drugs with varying chemical properties [2] . However, currently AFL has not been developed into clinical application for topical delivery of drugs otherwise delivered orally.
Basal cell carcinoma (BCC) is the most common form of cancer in the western world and represents 80% of conservatively estimated 2-3 million annual cases of nonmelanoma skin cancer worldwide, with an average annual increase in incidence of 3-8% observed since the 1960s [6, 7] . Deregulation of the Hedgehog pathway is present in 90-100% of sporadic BCC tumors, typically through mutations, which increase signaling activity [8] . Upregulation of this pathway seems essential for BCC development, thus increased interest have been placed on exploring the use of novel drugs to inhibit the hedgehog pathway, mainly through smoothened inhibitors, for the treatment of BCC. One of these, vismodegib, was approved in 2012 by the FDA for the treatment of advanced BCC. Vismodegib is administered orally with a daily dose of 150 mg [9] , however, treatment entails a high occurrence of class-specific systemic adverse reactions like dysgeusia, muscle spasms, and alopecia, with up to 25% serious adverse events shown in clinical trials, in all leading to treatment interruption and discontinuation for 12% of patients [10, 11] . Therefore, developing topical delivery systems of hedgehog inhibitors could lead to enhanced treatment of BCCs with limited systemic adverse effects and high patient compliance.
The formulation of vismodegib into a stable colloidal vehicle may be of crucial importance in order to achieve increased skin penetration and a controlled drug release. Micro-emulsions are fairly simple systems that allow the solubility of hydrophobic molecules, such as vismodegib, increasing their bioavailability and thus holding promise for topical drug delivery as they may facilitate increased drug uptake through the skin [1] . The present in vitro study aims to demonstrate the potential of combining the use of AFLassisted delivery and a novel micro-emulsion drug formulation for enhancing the topical delivery of vismodegib.
MATERIALS AND METHODS

Study Setup
The impact of AFL and drug formulation on topical uptake of vismodegib was studied in vitro using Franz diffusion cells and pig skin. Through a total of nine interventions, topical uptake of vismodegib in emulsion was investigated with and without laser exposure at 0.5, 4, and 24 hours, and as vehicle control, skin uptake of vismodegib in ethanol solution was investigated at 24 hours (Table 1) . Six repetitions were performed for each intervention (total n ¼ 54 samples). Vismodegib was detected using ultra performance liquid chromatography and mass spectrometry (UPLC-MS) at six skin depths from 0 to 1,800 mm (Table 2 ) and uptake was compared statistically at individual skin depth levels (Table 3) .
Vismodegib Formulation and Drug Information
Vismodegib (Adooq Bioscience, Irvine, CA) was formulated into an oil-in-water (O/W) micro-emulsion composed of phosphate buffer (10 mM PBS, pH 7.4) containing tween80 (0.5% w/v), soybean oil (10% v/v) and dimethylsulfoxide (DMSO, 3% v/v). The crude mixture was emulsified using a probe sonicator (QSonica, Newtown, CT) for 3 minutes in 1second pulse mode with amplitude set to 50%. As vehicle control, vismodegib was dissolved in pure ethanol. Vismodegib concentrations in both formulations were 2.7 mg/ml (6.4 mmol/L). The emulsion had a mean particle size distribution of approximately 250 nm, with a polydispersity index of 0.150 and being stable over time (>3 months). Chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Predicted partition coefficients for 1-octanol/water (LogP) were obtained from drugbank.ca (ALOGPS).
Skin Preparation and Laser Treatment
Following euthanasia, full-thickness flank skin was excised from one female Danish Yorkshire/Land race pig (45 kg). Hair and excessive subcutaneous fat was removed and skin was stored for a maximum of 3 months at À808C. Skin was equilibrated to room temperature prior to exposure to 10,600 nm fractional CO 2 -laser using (Ultrapulse 1 , DeepFx handpiece, Lumenis Inc, Santa Clara, CA) at 0 or 80 mJ/microbeam and 5% density. Microscopic ablation zone dimensions (median and interquartile range, n ¼ 13) were 780 mm (618-859 mm) deep, 159 mm (140-176 mm) wide and with a coagulation zone thickness of 51 mm (41-53 mm, Fig. 1 ).
Franz Cell Diffusion
Skin samples were mounted in Franz diffusion cells (PermeGear Inc., Hellertown, PA,) as previously described [12] at 378C with saline solution in receiver chambers. Donor chambers contained 1.0 ml of either vismodegib (in emulsion or ethanol) or PBS. After 0.5, 4, or 24 hours of incubation skin was removed from franz cells and from the center of the sample an 8 mm biopsy was excised, mounted in Tissue-Tek 
OCT
TM Compound (Sakura Finetek Europe B.V., Alphen aan den Rijn, The Netherlands) and snap-frozen. Biopsies were cut horizontally in sections of 30 mm thickness, collected at six specific skin depths (0-300, 300-600, 600-900. 900-1,200, 1,200-1,500, and 1,500-1,800 mm, 10 sections each) and kept frozen for vismodegib detection.
Detection of Vismodegib
Sectioned skin tissue samples were mixed with DMSO and homogenized with grinding balls at 30 Hz during Abbreviations: n, sample number per intervention (total n ¼ 54 samples); AFL, Ablative fractional laser; mb, microbeam. 
Statistics
Descriptive statistics (median and interquartile ranges) was evaluated and presented using GraphPad Prism (Version 5, GraphPad Software, La Jolla, CA). Vismodegib concentrations were analyzed separately for each skin depth comparing laser versus no laser, emulsion versus ethanol vehicle control and 24 hours versuss 0.5/4 hours by Mann-Whitney non-parametric analysis using IBM SPSS Statistics version 22 (International Business Machines Corp, Armonk, NY). Level of significance was set at P 0.05. Due to the limited number of comparisons for individual interventions, a post hoc analysis to correct for multiple comparisons was not performed.
RESULTS
Vismodegib Biodistribution in Skin
Vismodegib concentrations for different interventions and skin depths are shown in Table 2 with statistical comparisons summarized in Table 3 . For all drug-exposed interventions, vismodegib reached the highest deposition at superficial skin layers, while decreasing through deeper dermal layers. This pattern of vismodegib deposition is shown in Figure 2A . Figure 2B demonstrates vismodegib skin concentrations decreasing with increasing skin depths compared to patient vismodegib steady-state plasma concentrations (data from previous study on oral vismodegib administration (range 5.5-56.9 mmol/L)) [9] . 
Effect of Emulsion Formulation on Vismodegib Skin Concentrations
At 24 hours exposure, emulsion formulation improved the delivery of vismodegib into the upper skin compartments compared to vehicle control (Table 2 and (Fig. 2B) . Thus, combining laser and emulsion formulation for 24 hours resulted in a skin concentration of 7.6 fold higher than laser and vehicle control at 0-300 mm (P ¼ 0.002), 4.0 fold higher at 300-600 mm (P ¼ 0.002) and 2.3 fold higher at 600-900 mm (P ¼ 0.002). Furthermore, the vismodegib concentration obtained at 0-300 mm for combination of emulsion and AFL (24 hours exposure) was 9.7-101.6 fold higher than the range of steady-state plasma concentrations previously reported in patients treated with oral vismodegib [9] . No significant difference was detected between emulsion and vehicle control at deeper skin layers (900-1,800 mm).
Impact of AFL on Topical Vismodegib Uptake
In mid and deep dermis, a significant increase is observed for vismodegib uptake after 24 hours in AFL exposed skin compared to unexposed skin for emulsion formulation (300-1,800 mm, P ¼ 0.004-0.048, Fig. 2A ) and vehicle control (600-1,800 mm, P ¼ 0.002-0.015). At 24 hours, AFL increases total vismodegib uptake for the combined skin layers from 600 mm to 1,800 mm 8.2 fold for emulsion and 5.1 fold for ethanol vehicle control compared to intact skin. At 1,200-1,500 mm, concentrations in AFL exposed skin were 22.1 and 32.4 mmol/L (9.3 and 13.6 mg/cm 3 ) for emulsion and vehicle control, respectively, while corresponding concentrations in intact skin which were below the limit of detection (P ¼ 0.002-0.035). Table 1 . Gray shading indicates significance (P < 0.05). 24 hours displayed significantly enhanced deposition of vismodegib in AFL exposed skin at 0-300 mm and 600-900 mm compared with 4 hours (2.1-2.7 fold increase, P < 0.002-0.004). Even though not significant, a similar trend was observed at 1,200-1,500 mm. For intact skin the effect was only significant at 0-300 mm (P < 0.026 for 4 hours vs. 24 hours), whereas at 900-1,200 mm 24 hour treatment displayed lower concentrations compared to 4 hours (P < 0.013).
Vismodegib Skin Uptake Over Time
DISCUSSION
In this pioneering study we show for the first time that AFL exposure of skin enhances the topical delivery of vismodegib into skin, demonstrating the potential for local targeted therapy instead of conventional systemic administration. In addition, bypassing systemic adverse effects could lead to a more efficient treatment regimen for BCCs. In order to develop a successful treatment, it is mandatory that skin concentrations of vismodegib are clinically relevant even in 200, 1,200-1,500, and 1,500-1,800 mm) . The dashed horizontal lines indicates the highest (black, 56.9 mmol/L) and lowest (gray, 5.5 mmol/L) steady-state total vismodegib plasma concentration in patients receiving oral vismodegib measured by Graham et al [9] . Abbreviations: AFL, Ablative fractional laser. Selected statistics (for 24 hours treatment): AFL þ emulsion versus AFL þ vehicle control (ФФ ¼ P < 0.01); No AFL þ emulsion versus AFL þ emulsion ( Ã P < 0.05, ÃÃ P < 0.01).
the deepest parts of a tumor and that it remains on target for sufficient time. In this work we find that optimizing drug exposure time and formulation may increase vismodegib concentrations in epidermis and upper to mid dermal layers, while AFL facilitates delivery of vismodegib in mid and deep dermis compared to intact skin. To evaluate whether our findings are clinically relevant we compare the results to previously published data from patients treated with oral vismodegib. While vismodegib concentrations in tumors for standard oral treatment have not been published, pharmacokinetic studies for standard dosing in cancer patients revealed steady state plasma concentrations ranging from 5.5 to 56.9 mmol/L [9] . We have previously shown that IC 50 values for treating BCC tumor cells in vitro lies within this range [13] . This suggests that in lack of published vismodegib tumor concentrations, patient plasma concentration may serve as a surrogate marker for clinically relevant vismodegib concentrations.
Combining AFL and emulsion formulation (24 hours) yielded vismodegib concentrations remarkably above previously published plasma concentrations and IC 50 values for basal cell carcinoma cell lines at skin depths of 0-1,200 mm. At depths from 1,200 mm to 1,800 mm (24 hours), measured concentrations reached the range of patient plasma concentrations (Fig. 3C, Table 2 ), indicating that the treatment modality allows clinically relevant concentrations in all depths measured.
Reaching deeper skin depths is an issue in topical treatment of BCCs, which is currently primarily used for superficial tumors [14] . Thicker lesions may require drug delivery to deep skin layers difficult to reach by topical treatment. Notably, we find that AFL exposure specifically increases vismodegib concentrations significantly in mid and deep dermal skin compartments compared to intact skin. This may allow treatment of thicker BCC lesions with AFL-assisted topical delivery of vismodegib, though it should be noted that BCC lesions may be significantly thicker than the 1,800 mm depth achievable in the model using healthy skin.
Previous studies have shown that laser-assisted drug delivery depends on laser settings and drug characteristics such as its LogP (low for hydrophilic drugs and high for hydrophobic drugs). In the case of the hydrophilic drug 5-fluorouracil (LogP À0.58), AFL exposure increases uptake after 24 hours by 16-82 fold compared to intact skin and the effect is dependent on laser pulse energy [12] . On the other hand, the uptake of ingenol mebutate, a hydrophobic drug (LogP 2.49), was shown to increase only 1.6-3.9 fold in dermis after 21 hours depending on laser density but independent of laser pulse energy [15] . Similar results have been reported for diclofenac (LogP 4.98) with 1.4-2.9 fold increase in skin uptake after 24 hours depending on laser density [16] and in vivo for articaine/ epinephrine (LogP 1.9/À0.82) [17] , thus indicating that an increase in density might increase the topical uptake of vismodegib. For 5-fluorouracil and ingenol mebutate the effect of AFL exposure was more pronounced in deeper skin layers. Biodistribution was not resolved in individual skin layers for diclofenac as concentrations were only measured in full skin. Due to the hydrophobic nature of vismodegib (LogP 4.22) the most relevant drugs to compare with are ingenol mebutate and diclofenac. Specifically for the deeper skin compartments, the increase of vismodegib concentrations in AFL exposed skin compared to intact skin was more pronounced than previous data for ingenol mebutate and diclofenac. Importantly, vismodegib deposition is only increased twofold with AFL compared to intact skin if calculated for full skin (0-1,800 mm), for both emulsion and vehicle control. This highlights the importance of resolving drug concentrations in individual skin layers in studies on tissue biodistribution in AFL-assisted drug delivery. Further, it underlines that the effect of AFL is most pronounced on enhancing uptake in deep skin compartments, which are crucial to reach for treating BCCs efficiently.
In the present study a number of study limitations should also be considered. These include ex vivo study conditions, comparison of tissue and plasma vismodegib concentrations and vehicle control. Regarding the ex vivo study conditions, the use of the Franz cell model limits the study time-frame. Further, ex vivo skin lacks the active blood perfusion of dermis found in vivo which may lead to under-estimation of the elimination of drugs from the skin through blood and lymph. We believe this systemic elimination to be low for vismodegib due to its hydrophobic properties but this remains to be resolved in future in vivo experiments. Finally, we observe less deep microscopic ablation zones than theoretically expected based on the laser pulse energy used, which may be due to reduced hydration of the ex vivo skin.
While compared to previously reported plasma concentrations, vismodegib concentrations in this study are analyzed in skin tissue and further do not discriminate between intracellular and extracellular vismodegib. However, for oral vismodegib administration we expect tissue and intracellular concentrations in tumors would likely be lower than plasma concentrations. Therefore, we believe that relating the vismodegib concentrations found in this study to previously reported patient plasma concentrations to be a reasonable and conservative comparison. It should further be noted that for oral administration, more than 99% of vismodegib binds to plasma proteins such as alpha-1-acid glycoprotein. This leaves unbound vismodegib plasma concentrations of less than 0.1 mmol/L, though the unbound fraction is proportional to the total vismodegib concentrations [9] . Binding of vismodegib to alpha-1-acid glycoprotein may also occur locally in skin as the protein is present in interstitial fluids although only at 35% of the concentration found in plasma [18] .
Finally, selecting a suitable vehicle control posed a challenge. Vismodegib has very low solubility in aqueous solutions and more lipophilic vehicles might interact with the skin barrier. While ethanol may potentially have some effect on skin uptake [19] , we would expect alternatives such DMSO at concentrations necessary to dissolve vismodegib to have a larger impact on the skin barrier [20] . The low concentration of DMSO in our formulation is not expected to have a significant effect on skin integrity. Slightly higher vismodegib uptake from vehicle control compared to emulsion is observed in certain deep skin depths. However, the differences are far from significant (P ¼ 0.227-1.0) and may be due to variations in the individual experiments.
In conclusion, we show how topical treatment utilizing AFL in combination with a micro-emulsion drug formulation provides clinically relevant skin concentrations of vismodegib also in mid to deep dermis in vitro. Thus, we believe that the presented approach may hold great promise for the development of a novel treatment strategy based on topical delivery of vismodegib.
